|Description||CHS-828 is a synthetic guanidine-based small anticancer molecule. CHS 828 was found to exert potent cytotoxic effects in human breast and lung cancer cell lines, with lesser effects on normal fibroblasts and endothelial cells. In nude mice bearing human tumor xenografts, CHS 828, at doses from 20 to 50 mg/kg/day p.o., inhibited the growth of MCF-7 breast cancer tumors and caused regression of NYH small cell lung cancer tumors. Oral administration of CHS 828 once weekly improved efficacy without increasing toxicity. CHS 828 was found to compare favorably with established chemotherapeutic agents such as cyclophosphamide, etoposide, methotrexate, and paclitaxel. In mice with NYH tumors, long-term survival (>6 months) was observed after treatment with CHS 828 was stopped. CHS 828 is an effective new antitumor agent, with a potentially new mechanism of action. CHS-828 appeared to kill cancer cells by depleting NAD. CHS 828 is presently being tested in Phase I clinical trials in collaboration with the European Organization for Research and Treatment of Cancer.|
|Synonyms||CHS 828; CHS-828; GMX 1778.|
|Current Developer||Leo Pharmaceutical Products, Ballerup, Denmark.|
Nampt-IN-1, a pyridyloxyacetyl tetrahydroisoquinoline compound, is a novel inhibitor of nicotinamide phosphoribosyltransferase (NAMPT) with the potential to tre...
GNE-617 is a novel and specific Nampt inhibitor with an IC50 of 18.9 nM in A549 cell.
CHS-828 is a synthetic guanidine-based small anticancer molecule. CHS 828 was found to exert potent cytotoxic effects in human breast and lung cancer cell lines...
Daporinad, also known as APO-866 (FK866), is a small molecule with potential antineoplastic and antiangiogenic activities. In addition, this agent may inhibit ...
CB30865 is a highly potent cytotoxic agent. The compound inhibits isolated mammalian thymidylate synthase (TS), but this inhibition is insufficient to account f...
CB 300919 is a water-soluble analogue of CB30865; has a continuous exposure (96 h) growth inhibition IC50 value of 2 nM in human CH1 ovarian tumor xenograft.
STF-118804 is a potent and highly specific NAMPT inhibitor, which improves survival in an orthotopic xenotransplant model of high-risk acute lymphoblastic leuk...